| Literature DB >> 28853975 |
Susanna Esposito1, Sonia Bianchini2, Claudia Tagliabue2, Giulia Umbrello2, Barbara Madini2, Giada Di Pietro2, Nicola Principi2.
Abstract
Data regarding the use of technology to improve adolescent knowledge on vaccines are scarce. The main aim of this study was to evaluate whether different web-based educational programmes for adolescents might increase their vaccination coverage. Overall, 917 unvaccinated adolescents (389 males, 42.4%; mean age ± standard deviation, 14.0 ± 2.2 years) were randomized 1:1:1 into the following groups: no intervention (n = 334), website educational program only (n = 281), or website plus face to face lesson (n = 302) groups. The use of the website plus the lesson significantly increased the overall knowledge of various aspects of vaccine-preventable disease and reduced the fear of vaccines (p < 0.001). A significant increase in vaccination coverage was observed for tetanus, diphtheria, acellular pertussis and conjugated meningococcal ACYW vaccines in the 2 groups using the website (p < 0.001), and better results were observed in the group that had also received the lesson; in this last group, significant results were observed in the increase in vaccination coverage for meningococcal B vaccine (p < 0.001). Overall, the majority of the participants liked the experience of the website, although they considered it important to further discuss vaccines with parents, experts and teachers. This study is the first to evaluate website based education of adolescents while considering all of the vaccines recommended for this age group. Our results demonstrate the possibility of increasing vaccination coverage by using a website based educational program with tailored information. However, to be most effective, this program should be supplemented with face-to-face discussions of vaccines at school and at home. Thus, specific education should also include teachers and parents so that they will be prepared to discuss with adolescents what is true and false in the vaccination field.Entities:
Keywords: adolescents; educational programmeprogram; vaccination coverage; vaccine; web-sitewebsite
Mesh:
Substances:
Year: 2018 PMID: 28853975 PMCID: PMC5893194 DOI: 10.1080/21645515.2017.1359453
Source DB: PubMed Journal: Hum Vaccin Immunother ISSN: 2164-5515 Impact factor: 3.452
Baseline characteristics of the study population according to randomized group.
| Characteristic | No intervention (n = 334) | Web-site only (n = 281) | Web-site + lesson (n = 302) | p-value |
|---|---|---|---|---|
| Mean ± SD | 14.1 ± 2.3 | 13.8 ± 2.3 | 13.6 ± 2.0 | |
| Male | 150 (44.9) | 131 (46.6) | 108 (35.8) | |
| Female | 184 (55.1) | 150 (53.4) | 194 (64.2) | |
| Italian | 275 (83.1) | 243 (86.8) | 246 (81.7) | |
| Other | 56 (16.9) | 37 (13.2) | 55 (18.3) | 0.23 |
| No | 318 (95.2) | 268 (95.4) | 285 (94.4) | |
| Yes | 16 (4.8) | 13 (4.6) | 17 (5.6) | 0.83 |
| No | 48 (14.4) | 57 (20.3) | 64 (21.2) | |
| Yes | 286 (85.6) | 224 (79.7) | 238 (78.8) | 0.054 |
The numbers do not add up to the total because of several missing values
Personal knowledge and attitude toward vaccinations before and after intervention according to randomization group in subjects who completed the study.
| No intervention (n = 286) | Web-site only (n = 224) | Web-site + lesson (n = 238) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Knowledge and attitude | Answer at baseline | Answer after intervention | p-value | Answer at baseline | Answer after intervention | p-value | Answer at baseline | Answer after intervention | p-value |
| Yes | 189 (66.1) | 194 (68.3) | 139 (62.0) | 158 (70.8) | 142 (59.7) | 169 (71.9) | |||
| No/Only those having chronic diseases/Don't know | 97 (33.9) | 90 (31.7) | 0.54 | 85 (38.0) | 65 (29.2) | 96 (40.3) | 66 (28.1) | ||
| They are useful to prevent diseases in vaccinated and non-vaccinated people | 224 (79.1) | 241 (84.6) | 169 (75.8) | 174 (78.0) | 184 (77.3) | 203 (86.4) | |||
| Other answers/Don't know | 59 (20.9) | 44 (15.4) | 54 (24.2) | 49 (22.0) | 0.43 | 54 (22.7) | 32 (13.6) | ||
| Airborne route | 196 (68.5) | 181 (63.5) | 160 (71.4) | 159 (71.0) | 156 (65.5) | 179 (76.2) | |||
| Other answers/Don't know | 90 (31.5) | 104 (36.5) | 0.08 | 64 (28.6) | 65 (29.0) | 0.90 | 82 (34.5) | 56 (23.8) | |
| Airborne route | 149 (52.1) | 128 (44.9) | 115 (51.6) | 105 (46.9) | 126 (53.2) | 134 (57.5) | |||
| Other answers/Don't know | 137 (47.9) | 157 (55.1) | 108 (48.4) | 119 (53.1) | 0.27 | 111 (46.8) | 99 (42.5) | 0.32 | |
| Through skin wounds, animal bites or injections | 236 (82.5) | 233 (81.7) | 188 (83.9) | 181 (80.8) | 201 (84.4) | 203 (86.7) | |||
| Other answers/Don't know | 50 (17.5) | 52 (18.3) | 0.78 | 36 (16.1) | 43 (19.2) | 0.24 | 37 (15.6) | 31 (13.3) | 0.46 |
| Airborne route | 228 (79.7) | 215 (76.0) | 181 (80.8) | 175 (78.5) | 190 (79.8) | 192 (82.4) | |||
| Other answers/Don't know | 58 (20.3) | 68 (24.0) | 0.18 | 43 (19.2) | 48 (21.5) | 0.49 | 48 (20.2) | 41 (17.6) | 0.48 |
| Sexual route | 232 (82.3) | 201 (71.0) | 187 (83.9) | 176 (78.6) | 194 (82.5) | 203 (86.4) | |||
| Other answers/Don't know | 50 (17.7) | 82 (29.0) | 36 (16.1) | 48 (21.4) | 0.12 | 41 (17.5) | 32 (13.6) | 0.22 | |
| No | 194 (68.1) | 214 (75.1) | 147 (65.6) | 164 (73.2) | 152 (63.9) | 181 (77.0) | |||
| Yes/Only some of them/I don't know | 91 (31.9) | 71 (24.9) | 77 (34.4) | 60 (26.8) | 86 (36.1) | 54 (23.0) | |||
| Yes | 240 (84.2) | 246 (86.6) | 180 (80.4) | 195 (87.0) | 198 (83.2) | 205 (87.2) | |||
| No/Just some/I don't know | 45 (15.8) | 38 (13.4) | 0.31 | 44 (19.6) | 29 (13.0) | 40 (16.8) | 30 (12.8) | 0.11 | |
The numbers may not add up to the total because of several missing values.
p-values from McNemar's test for paired data.
Frequency of specific vaccinations after presentation of the project at school in 748 subjects who completed the study, according to randomization group.
| Overall (n = 748) | No intervention (n = 284) | Web-site only (n = 224) | Web-site + lesson (n = 238) | ||
|---|---|---|---|---|---|
| Vaccination | n (%) | n (%) | n (%) | n (%) | p-value |
| Tdap booster | 262 (35.1) | 15 (5.3) | 99 (44.2) | 148 (62.2) | |
| MenACYW vaccine | 182 (24.4) | 3 (1.1) | 52 (23.2) | 127 (53.4) | |
| HPV vaccine | 44 (5.9) | 17 (6.0) | 9 (4.0) | 18 (7.6) | 0.27 |
| MenB vaccine | 41 (5.5) | 0 (0.0) | 0 (0.0) | 41 (17.2) | |
| MenC vaccine | 9 (1.2) | 1 (0.3) | 4 (1.8) | 4 (1.7) | NE |
| Chickenpox vaccine | 2 (0.3) | 0 (0.0) | 0 (0.0) | 2 (0.8) | NE |
| Influenza vaccine | 2 (0.3) | 1 (0.3) | 0 (0.0) | 1 (0.4) | NE |
Two subjects (in group A) had follow-up contact but did not answer questions on vaccinations performed during follow-up
HPV: human papillomavirus; MenACYW: conjugated meningococcal ACYW vaccine; MenB: meningococcal B vaccine; Tdap: tetanus, diphtheria, acellular pertussis; and NE: not estimable because of the small number of vaccinated subjects.
Association between vaccination and randomization group after intervention.
| Vaccination | OR (95% CI) | p-value |
|---|---|---|
| No intervention | 1 (reference) | — |
| Web-site only | ||
| Web-site + lesson | ||
| No intervention | 1 (reference) | — |
| Web-site only | ||
| Web-site + lesson | ||
| No intervention | 1 (reference) | — |
| Web-site only | ||
| Web-site + lesson | ||
| No intervention | 1 (reference) | — |
| Web-site only | ||
| Web-site + lesson | ||
| No intervention | 1 (reference) | — |
| Web-site only | ||
| Web-site + lesson |
ORs adjusted for age, sex, nationality, and presence of chronic diseases.
95% CI: 95% confidence interval; OR: odds ratio.
Satisfaction of subjects in the 2 intervention groups regarding the website educational program, according to sex and age.
| Web-site only group (n = 281) | Web-site + lesson (n = 302) | p-value | Males (n = 239) | Females (n = 344) | p-value | Age <14 (n = 275) | Age 14+ (n = 307) | p-value | |
|---|---|---|---|---|---|---|---|---|---|
| Clarity of language | 4.0 ± 1.1 | 4.0 ± 0.9 | 0.98 | 4.0 ± 1.2 | 4.0 ± 0.8 | 0.39 | 3.7 ± 1.3 | 4.1 ± 0.8 | 0.08 |
| Clarity of contents | 3.9 ± 1.1 | 4.1 ± 1.0 | 0.32 | 3.9 ± 1.2 | 4.1 ± 0.9 | 0.99 | 3.7 ± 1.3 | 4.1 ± 0.9 | 0.12 |
| Easy navigation | 4.0 ± 1.1 | 3.9 ± 1.0 | 0.82 | 3.9 ± 1.2 | 4.0 ± 0.9 | 0.52 | 3.7 ± 1.3 | 4.1 ± 0.9 | 0.16 |
| Web design | 3.8 ± 1.2 | 3.9 ± 1.1 | 0.42 | 3.8 ± 1.3 | 3.9 ± 1.0 | 0.86 | 3.7 ± 1.3 | 3.9 ± 1.1 | 0.53 |
| Overall satisfaction | 3.8 ± 1.1 | 4.0 ± 1.0 | 0.43 | 3.8 ± 1.2 | 4.0 ± 0.8 | 0.94 | 3.7 ± 1.2 | 4.0 ± 0.9 | 0.22 |
| Less than 1 minute | 12 (14.8) | 17 (16.3) | 17 (21.0) | 12 (11.5) | 20 (30.8) | 9 (7.5) | |||
| 2 to 4 minutes | 24 (29.6) | 23 (22.1) | 22 (27.2) | 25 (24.0) | 8 (12.3) | 39 (32.5) | |||
| 5 to 15 minutes | 37 (45.7) | 52 (50.0) | 29 (35.8) | 60 (57.7) | 26 (40.0) | 63 (52.5) | |||
| 16 minutes or more | 8 (9.9) | 12 (11.5) | 0.71 | 13 (16.0) | 7 (6.7) | 11 (16.9) | 9 (7.5) | ||
| Immune system | 18 (24.3) | 24 (28.2) | 21 (31.8) | 21 (22.6) | 10 (24.4) | 32 (27.1) | |||
| Response against pathogen | 6 (8.1) | 11 (12.9) | 5 (7.6) | 12 (12.9) | 3 (7.3) | 14 (11.9) | |||
| Vaccines | 24 (32.4) | 24 (28.2) | 21 (31.8) | 27 (29.0) | 13 (31.7) | 35 (29.7) | |||
| Risk and protective factors for infectious disease | 10 (13.5) | 12 (14.1) | 9 (13.6) | 13 (14.0) | 7 (17.1) | 15 (12.7) | |||
| Vaccine-preventable diseases | 13 (17.6) | 10 (11.8) | 8 (12.1) | 15 (16.1) | 6 (14.6) | 17 (14.4) | |||
| Other | 3 (4.0) | 4 (4.7) | 0.81 | 2 (3.0) | 5 (5.4) | 0.66 | 2 (4.9) | 5 (4.2) | 0.95 |
| Vaccine mechanism of action | 14 (18.7) | 5 (6.1) | 8 (12.5) | 11 (11.8) | 0.90 | 10 (25.0) | 9 (7.7) | ||
| Vaccine safety | 17 (22.7) | 20 (24.4) | 0.80 | 21 (32.8) | 16 (17.2) | 19 (47.5) | 18 (15.4) | ||
| The body's defense mechanisms | 6 (8.0) | 7 (8.5) | 0.9 | 4 (6.2) | 9 (9.7) | 0.44 | 2 (5.0) | 11 (9.4) | 0.52 |
| Infectious diseases | 11 (14.7) | 22 (26.8) | 0.06 | 15 (23.4) | 18 (19.3) | 0.54 | 8 (20.0) | 25 (21.4) | 0.85 |
| Advice for infectious disease prevention | 20 (26.7) | 13 (15.8) | 0.10 | 12 (18.7) | 21 (22.6) | 0.56 | 4 (10.0) | 29 (24.8) | |
| Vaccine scepticism | 19 (25.3) | 17 (20.7) | 0.49 | 10 (15.6) | 26 (28.0) | 0.07 | 6 (15.0) | 30 (25.6) | 0.17 |
| Other | 5 (6.7) | 6 (7.3) | 0.87 | 5 (7.8) | 6 (6.4) | 0.74 | 1 (2.5) | 10 (8.5) | 0.29 |
| No | 104 (75.9) | 111 (76.5) | 96 (78.7) | 119 (74.4) | 81 (76.4) | 134 (76.1) | |||
| Yes | 33 (24.1) | 34 (23.5) | 0.90 | 26 (21.3) | 41 (25.6) | 0.40 | 25 (23.6) | 42 (23.9) | 0.96 |
| No | 97 (79.5) | 112 (81.2) | 87 (80.6) | 122 (80.3) | 68 (73.9) | 141 (83.9) | |||
| Yes | 25 (20.5) | 26 (18.8) | 0.74 | 21 (19.4) | 30 (19.7) | 0.95 | 24 (26.1) | 27 (16.1) | 0.052 |
| I didn't like my experience with this website, and I considered it useless | 10 (13.3) | 4 (4.5) | 8 (12.1) | 6 (6.2) | 0 (0.0) | 14 (11.9) | |||
| I liked my experience with this website, but I would like to meet again with people who recommended it to me, to discuss specific questions | 11 (14.7) | 8 (9.1) | 9 (13.6) | 10 (10.3) | 2 (4.4) | 17 (14.4) | |||
| I liked my experience with this website, but I would like to discuss it further with my parents | 6 (8.0) | 19 (21.6) | 6 (9.1) | 19 (19.6) | 7 (15.6) | 18 (15.2) | |||
| I liked my experience with this website, but I would like to discuss it further with my teachers | 11 (14.7) | 13 (14.8) | 8 (12.1) | 16 (16.5) | 5 (11.1) | 19 (16.1) | |||
| I'm really satisfied with my experience with this website | 37 (49.3) | 44 (50.0) | 35 (53.0) | 46 (47.4) | 0.23 | 31 (68.9) | 50 (42.4) |